Form 4: Amgen VP Matthew Busch Reports Stock Transaction

Amgen VP of Finance and CAO Matthew C. Busch reported the disposition of 41 shares of common stock to cover tax obligations.

Summary

• Matthew C. Busch, VP of Finance and CAO at Amgen Inc., disposed of 41 shares of common stock.
• The transaction occurred on May 7, 2026, at a price of $331.11 per share.
• The disposition was executed to satisfy tax withholding obligations related to the vesting of equity awards.
• Following this transaction, the reporting person maintains beneficial ownership of 4,344 shares of Amgen common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a mandatory administrative process for tax compliance rather than a market-driven trade.

Positives

• The transaction was a routine administrative action related to tax withholding rather than a discretionary sale of shares.

Negatives

• Reduction in the reporting person's direct equity stake in the company.

Risks

• None identified; this is a standard regulatory disclosure for executive compensation tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that Form 4 filings regarding tax withholding are standard industry practice for executives receiving equity-based compensation and do not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for large-cap pharmaceutical companies where executives frequently settle tax liabilities through share withholding.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was for tax withholding purposes.

Next Steps

• None; this is a retrospective disclosure of a completed transaction.

Key Dates

Keywords

Amgen, AMGN, Form 4, Insider Trading, Executive Compensation, Stock Disposition